The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...
PDUFA: June 10, 2025 Indication: Respiratory syncytial virus Summary: December 17, 2024, Merck announced that the FDA has accepted the Biologics License Application (BLA) for clesrovimab, a monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback